Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Translational Allergy"
DOI: 10.1002/clt2.12063
Abstract: To the Editor, Patients with severe eosinophilic asthma experience frequent exacerbations and may require oral corticosteroids (OCS) to maintain asthma control. In randomized controlled trials (RCTs), the anti‐interleukin‐5 monoclonal antibody, mepolizumab, reduces exacerbation rates and… read more here.
Keywords: study; index; treatment; mepolizumab ... See more keywords
La pharmacocinétique et la pharmacodynamie du mépolizumab chez les enfants âgés entre 6 et 11 ans avec un asthme sévère éosinophilique
Sign Up to like & getrecommendations! Published in 2019 at "Revue des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2018.10.113
Abstract: Resume Introduction L’anticorps monoclonal anti-IL5 mepolizumab a ete approuve par l’UE, les Etats-Unis et d’autres marches internationaux comme traitement additionnel au traitement de fond chez les patients adultes avec un asthme severe eosinophilique (ASE). Dans plusieurs… read more here.
Keywords: ont recu; ans avec; chez les; avec asthme ... See more keywords
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Asthma"
DOI: 10.1080/02770903.2020.1837158
Abstract: Abstract Objective To evaluate the cost-effectiveness of mepolizumab added to standard of care (SOC) compared with SOC alone among patients with severe uncontrolled eosinophilic asthma in the Singapore setting. Methods A Markov model with three… read more here.
Keywords: cost effectiveness; cost; care; mepolizumab ... See more keywords
Impact of mepolizumab in patients with high-burden severe asthma within a managed care population
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma"
DOI: 10.1080/02770903.2022.2102036
Abstract: Abstract Objective To evaluate the real-world impact of mepolizumab on the incidence of asthma exacerbations, oral corticosteroid (OCS) use and asthma exacerbation-related costs in patients with high-burden severe asthma. Methods This was a retrospective study… read more here.
Keywords: patients high; asthma exacerbation; mepolizumab; exacerbation ... See more keywords
SP0119 The evolving role of mepolizumab in egpa
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7727
Abstract: There is overwhelming evidence that eosinophiles play a key role in the pathogenesis of EGPA. Il-5 is the central cytokine for eosinophil maturation, eosinophil release from the bone marrow and eosinophil survival. Mepolizumab is an… read more here.
Keywords: evolving role; mepolizumab; remission; mepolizumab egpa ... See more keywords
P134 Real world experience of mepolizumab in steroid-dependent severe eosinophilic asthma: one year outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Thorax"
DOI: 10.1136/thorax-2018-212555.292
Abstract: Introduction Mepolizumab is a monoclonal antibody against IL-5 and is licensed for treatment of severe eosinophilic asthma (SEA). In clinical trials, most patients dependent on maintenance oral prednisolone (mOCS) were able to reduce or stop… read more here.
Keywords: treatment; one year; asthma; mocs ... See more keywords
P71 Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one centre’s experience
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.213
Abstract: Introduction Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma.1 The Scottish Medicines Commission has accepted it for restricted use in adults as an add-on… read more here.
Keywords: asthma eligible; severe eosinophilic; mepolizumab; eosinophilic asthma ... See more keywords
Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Sign Up to like & getrecommendations! Published in 2021 at "International archives of allergy and immunology"
DOI: 10.1159/000519228
Abstract: INTRODUCTION Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, there lacks a head-to-head randomized trial comparing biologics. We aimed… read more here.
Keywords: meta analysis; nasal polyps; efficacy; network meta ... See more keywords
Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience
Sign Up to like & getrecommendations! Published in 2022 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000526410
Abstract: Introduction: Data showing effectiveness of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) are limited. Methods: This is a single-center retrospective chart review of patients with EGPA treated with mepolizumab. Clinical, laboratory, functional parameters… read more here.
Keywords: month; mepolizumab; life; egpa ... See more keywords
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2020.5280
Abstract: Background: The long-term efficacy and safety of mepolizumab in severe eosinophilic asthma (SEA) have been shown. Aims: To assess the impact of stopping versus continuing long-term mepolizumab on asthma worsening. Methods: COMET (NCT02555371) was a… read more here.
Keywords: long term; asthma worsening; term mepolizumab; mepolizumab ... See more keywords
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Sign Up to like & getrecommendations! Published in 2017 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s150656
Abstract: Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines… read more here.
Keywords: severe eosinophilic; eosinophilic asthma; pathogenic role; asthma ... See more keywords